<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01942681</url>
  </required_header>
  <id_info>
    <org_study_id>TRIGU1309</org_study_id>
    <secondary_id>UMIN000011491</secondary_id>
    <nct_id>NCT01942681</nct_id>
  </id_info>
  <brief_title>Female Patients With Signs of uRgE and Stress Urinary Incontinence Study of Propiverine Hydrochloride</brief_title>
  <acronym>FRESH</acronym>
  <official_title>Multi-institution Study on Efficacy and Safety of Propiverine Hydrochloride for Female Patients With Urge and Stress Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shinshu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the efficacy and safety that the occurrence of incontinence is&#xD;
      significantly decrease using the propiverine hydrochloride for 200 female patients with mixed&#xD;
      (stress and urge) urinary incontinence in one week during a twelve-week treatment period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of incontinence</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <description>Change in occurrence of incontinence during a twelve-week treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of protective pad used</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <description>Change in the number of protective pad used during a twelve-week treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction ratio of the occurrence for incontinence</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <description>Change in reduction ratio of the occurrence for incontinence during a twelve-week treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICIQ-Short Form(SF) scores</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <description>Change in ICIQ-SF scores during a twelve-week treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>I-QOL scores</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <description>Change in I-QOL scores during a twelve-week treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPSS-QOL scores</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <description>Change in IPSS-QOL scores during a twelve-week treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPSS symptom scores</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <description>Change in IPSS symptom scores during a twelve-week treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OABSS symptom scores</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <description>Change in OABSS symptom scores during a twelve-week treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <description>Change in blood pressure during a twelve-week treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse rate</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <description>Change in pulse rate during a twelve-week treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <description>The occurrence of adverse events during a twelve-week treatment period</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Maximum urethral closure pressure</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <description>Change in maximum urethral closure pressure during a twelve-week treatment period</description>
  </other_outcome>
  <other_outcome>
    <measure>Functional profile length</measure>
    <time_frame>during a twelve-week treatment period</time_frame>
    <description>Change in functional profile length during a twelve-week treatment period</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Propiverine Hydrochloride Administration</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Administration of Propiverine Hydrochloride for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propiverine Hydrochloride</intervention_name>
    <description>Administrate Propiverine Hydrochloride for 12 weeks</description>
    <arm_group_label>Propiverine Hydrochloride Administration</arm_group_label>
    <other_name>Bup-4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female patients with mixed urinary incontinence (MUI)&#xD;
&#xD;
          2. Patients having symptoms of urinary incontinence for at least 3 months&#xD;
&#xD;
          3. Patients having at least one episode of urge urinary incontinence per week and 4&#xD;
             episodes of stress urinary incontinence per week in a bladder diary.&#xD;
&#xD;
          4. 20 years old or older&#xD;
&#xD;
          5. Patients who meet all the following criteria in ICIQ-SF (1) &quot;2-3 times or more in one&#xD;
             week&quot; was selected at Q1. (2) &quot;Small or more&quot; was selected at Q2. (3) &quot;leak at the&#xD;
             time of cough or sneeze&quot; or &quot;leak at the time of exercise&quot; was selected at Q4.&#xD;
&#xD;
          6. Less than 100mL of residual urine volume&#xD;
&#xD;
          7. Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with organ disease such as bladder stones, bladder tumors and urethral&#xD;
             stricture in the lower urinary tract&#xD;
&#xD;
          2. Patients with bacterial infections (i.e. bacterial cystitis) or nonbacterial&#xD;
             infections (i.e. interstitial cystitis)&#xD;
&#xD;
          3. Patients with advanced lower urinary tract obstruction or urinary retention&#xD;
&#xD;
          4. Patients without urinary sensation&#xD;
&#xD;
          5. Patients with overflow incontinence&#xD;
&#xD;
          6. Patients with history or complications of pelvic organ prolapse&#xD;
&#xD;
          7. Patients with pyloric, duodenal or intestinal obstruction&#xD;
&#xD;
          8. Patients with gastric or intestinal atony&#xD;
&#xD;
          9. Patients with angle-closure glaucoma&#xD;
&#xD;
         10. Patients with myasthenia gravis&#xD;
&#xD;
         11. Patients with severe heart disease&#xD;
&#xD;
         12. Patients with severe constipation&#xD;
&#xD;
         13. Patients with dementia who are not able to complete the questionnaires&#xD;
&#xD;
         14. Patients with history of allergic reaction to Propiverine Hydrochloride or other&#xD;
             similar medicine&#xD;
&#xD;
         15. Patients with history of surgery that affect urination such as Trans-Obturator&#xD;
             Tape（TOT）or Tension-free Vaginal Tape（TVT）&#xD;
&#xD;
         16. Women who are pregnant, lactating, potentially pregnant or willing to get pregnant&#xD;
&#xD;
         17. Patients with previous surgery of the abdomen and pelvis or radiation within 6 months&#xD;
&#xD;
         18. Patients who started pelvic floor muscle exercise within 3 months&#xD;
&#xD;
         19. Patients who took Propiverine Hydrochloride or other similar medicine within 2 weeks&#xD;
             before entry&#xD;
&#xD;
         20. Judged as being unsuitable for the trial by physician.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osamu Nishizawa, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shinshu University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shinshu University Hospital</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <zip>390-8621</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>August 29, 2013</study_first_submitted>
  <study_first_submitted_qc>September 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2013</study_first_posted>
  <last_update_submitted>July 14, 2015</last_update_submitted>
  <last_update_submitted_qc>July 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>female</keyword>
  <keyword>mixed urinary incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propiverine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

